ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) saw a large decrease in short interest in January. As of January 31st, there was short interest totalling 4,400 shares, a decrease of 15.4% from the January 15th total of 5,200 shares. Based on an average trading volume of 11,900 shares, the short-interest ratio is presently 0.4 days.
Institutional Investors Weigh In On ProShares Ultra Nasdaq Biotechnology
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BIB. Crowley Wealth Management Inc. purchased a new position in shares of ProShares Ultra Nasdaq Biotechnology during the 4th quarter worth $51,000. Jane Street Group LLC lifted its position in ProShares Ultra Nasdaq Biotechnology by 8.4% in the third quarter. Jane Street Group LLC now owns 4,803 shares of the exchange traded fund's stock valued at $306,000 after buying an additional 374 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in ProShares Ultra Nasdaq Biotechnology by 31.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,326 shares of the exchange traded fund's stock worth $270,000 after buying an additional 1,266 shares during the period.
ProShares Ultra Nasdaq Biotechnology Trading Up 1.8 %
BIB traded up $0.99 during trading on Wednesday, reaching $56.45. The company's stock had a trading volume of 7,549 shares, compared to its average volume of 10,608. The firm has a fifty day simple moving average of $53.24 and a two-hundred day simple moving average of $59.33. ProShares Ultra Nasdaq Biotechnology has a 1 year low of $47.19 and a 1 year high of $69.56.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
The firm also recently disclosed a dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 23rd were issued a $0.3964 dividend. The ex-dividend date of this dividend was Monday, December 23rd. This is a boost from ProShares Ultra Nasdaq Biotechnology's previous dividend of $0.15.
About ProShares Ultra Nasdaq Biotechnology
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Read More
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
